Your browser doesn't support javascript.
SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.
Ward, Helen; Atchison, Christina; Whitaker, Matthew; Ainslie, Kylie E C; Elliott, Joshua; Okell, Lucy; Redd, Rozlyn; Ashby, Deborah; Donnelly, Christl A; Barclay, Wendy; Darzi, Ara; Cooke, Graham; Riley, Steven; Elliott, Paul.
  • Ward H; School of Public Health, Imperial College London, London, UK. h.ward@imperial.ac.uk.
  • Atchison C; National Institute for Health Research Imperial Biomedical Research Centre, London, UK. h.ward@imperial.ac.uk.
  • Whitaker M; Imperial College Healthcare NHS Trust, London, UK. h.ward@imperial.ac.uk.
  • Ainslie KEC; School of Public Health, Imperial College London, London, UK.
  • Elliott J; School of Public Health, Imperial College London, London, UK.
  • Okell L; School of Public Health, Imperial College London, London, UK.
  • Redd R; MRC Centre for Global Infectious Disease Analysis Imperial College London, London, UK.
  • Ashby D; School of Public Health, Imperial College London, London, UK.
  • Donnelly CA; School of Public Health, Imperial College London, London, UK.
  • Barclay W; MRC Centre for Global Infectious Disease Analysis Imperial College London, London, UK.
  • Darzi A; School of Public Health, Imperial College London, London, UK.
  • Cooke G; School of Public Health, Imperial College London, London, UK.
  • Riley S; School of Public Health, Imperial College London, London, UK.
  • Elliott P; MRC Centre for Global Infectious Disease Analysis Imperial College London, London, UK.
Nat Commun ; 12(1): 905, 2021 02 10.
Article in English | MEDLINE | ID: covidwho-1078587
ABSTRACT
England has experienced a large outbreak of SARS-CoV-2, disproportionately affecting people from disadvantaged and ethnic minority communities. It is unclear how much of this excess is due to differences in exposure associated with structural inequalities. Here, we report from the REal-time Assessment of Community Transmission-2 (REACT-2) national study of over 100,000 people. After adjusting for test characteristics and re-weighting to the population, overall antibody prevalence is 6.0% (95% CI 5.8-6.1). An estimated 3.4 million people had developed antibodies to SARS-CoV-2 by mid-July 2020. Prevalence is two- to three-fold higher among health and care workers compared with non-essential workers, and in people of Black or South Asian than white ethnicity, while age- and sex-specific infection fatality ratios are similar across ethnicities. Our results indicate that higher hospitalisation and mortality from COVID-19 in minority ethnic groups may reflect higher rates of infection rather than differential experience of disease or care.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-21237-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-21237-w